BioWorld20h
Apollo signs near-$1B deal for Sunshine’s FGF21/GLP-1 injection
Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual fibroblast growth factor 21 ...
BioWorld20h
Biopharma deal value, down for year, surges 72% in October
Biopharma deal activity in October totaled $22.31 billion, marking a 72% jump from $13.01 billion in September. Year-to-date deal values have decreased by 2%, from $175.29 billion during the first 10 ...
BioWorld20h
‘A decade of innovation, a decade to come’ for China pharma
As China rises to second place, next only to the U.S., for innovative new drugs, a new report by Clarivate – A Decade of Innovation, A Decade to Come – outlines key policy reforms and regulatory, R&D ...
BioWorld21h
Gender bias leaves women at risk in cardiology treatment guidelines
Gender bias in cardiac treatment guidelines is putting women at risk because guidelines are written based on clinical trials conducted mostly in men. As previously reported in BioWorld, nearly 70% of ...